| Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining T Maruyama, SK Dougan, MC Truttmann, AM Bilate, JR Ingram, ... Nature biotechnology 33 (5), 538-542, 2015 | 1317 | 2015 |
| CEACAM1 regulates TIM-3-mediated tolerance and exhaustion YH Huang, C Zhu, Y Kondo, AC Anderson, A Gandhi, A Russell, ... Nature 517 (7534), 386-390, 2015 | 660 | 2015 |
| GM-CSF, IL-3, and IL-5 family of cytokines: regulators of inflammation M Dougan, G Dranoff, SK Dougan Immunity 50 (4), 796-811, 2019 | 376 | 2019 |
| The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy JA Krall, F Reinhardt, OA Mercury, DR Pattabiraman, MW Brooks, ... Science translational medicine 10 (436), eaan3464, 2018 | 376 | 2018 |
| Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities VP Balachandran, GL Beatty, SK Dougan Gastroenterology 156 (7), 2056-2072, 2019 | 369 | 2019 |
| Molecular pathways of colon inflammation induced by cancer immunotherapy AM Luoma, S Suo, HL Williams, T Sharova, K Sullivan, M Manos, ... Cell 182 (3), 655-671. e22, 2020 | 326 | 2020 |
| In vivo discovery of immunotherapy targets in the tumour microenvironment P Zhou, DR Shaffer, DA Alvarez Arias, Y Nakazaki, W Pos, AJ Torres, ... Nature 506 (7486), 52-57, 2014 | 261 | 2014 |
| Sortase-catalyzed transformations that improve the properties of cytokines MW Popp, SK Dougan, TY Chuang, E Spooner, HL Ploegh Proceedings of the National Academy of Sciences 108 (8), 3169-3174, 2011 | 231 | 2011 |
| Engineered red blood cells as carriers for systemic delivery of a wide array of functional probes J Shi, L Kundrat, N Pishesha, A Bilate, C Theile, T Maruyama, SK Dougan, ... Proceedings of the National Academy of Sciences 111 (28), 10131-10136, 2014 | 227 | 2014 |
| XBP‐1 regulates signal transduction, transcription factors and bone marrow colonization in B cells CCA Hu, SK Dougan, AM McGehee, JC Love, HL Ploegh The EMBO journal 28 (11), 1624-1636, 2009 | 223 | 2009 |
| Profiling lymphocyte interactions at the single-cell level by microfluidic cell pairing B Dura, SK Dougan, M Barisa, MM Hoehl, CT Lo, HL Ploegh, J Voldman Nature communications 6 (1), 5940, 2015 | 188 | 2015 |
| Microsomal triglyceride transfer protein lipidation and control of CD1d on antigen-presenting cells SK Dougan, A Salas, P Rava, A Agyemang, A Kaser, J Morrison, ... The Journal of experimental medicine 202 (4), 529-539, 2005 | 185 | 2005 |
| The pancreatic cancer microenvironment SK Dougan The Cancer Journal 23 (6), 321-325, 2017 | 184 | 2017 |
| Eosinophils in health and disease: a state-of-the-art review ME Wechsler, A Munitz, SJ Ackerman, MG Drake, DJ Jackson, ... Mayo Clinic Proceedings 96 (10), 2694-2707, 2021 | 172 | 2021 |
| CD1 expression on antigen-presenting cells SK Dougan, A Kaser, RS Blumberg T Cell Activation by CD1 and Lipid Antigens, 113-141, 2007 | 172 | 2007 |
| Cancer immunotherapy: beyond checkpoint blockade M Dougan, G Dranoff, SK Dougan Annual Review of Cancer Biology 3 (1), 55-75, 2019 | 164 | 2019 |
| Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease N Pishesha, AM Bilate, MC Wibowo, NJ Huang, Z Li, R Deshycka, ... Proceedings of the National Academy of Sciences 114 (12), 3157-3162, 2017 | 154 | 2017 |
| Preparation of unnatural N-to-N and C-to-C protein fusions MD Witte, JJ Cragnolini, SK Dougan, NC Yoder, MW Popp, HL Ploegh Proceedings of the National Academy of Sciences 109 (30), 11993-11998, 2012 | 153 | 2012 |
| Understanding and treating the inflammatory adverse events of cancer immunotherapy M Dougan, AM Luoma, SK Dougan, KW Wucherpfennig Cell 184 (6), 1575-1588, 2021 | 151 | 2021 |
| EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer KL Morel, AV Sheahan, DL Burkhart, SC Baca, N Boufaied, Y Liu, X Qiu, ... Nature cancer 2 (4), 444-456, 2021 | 147 | 2021 |
